SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nura Bio Inc. (Nura Bio), a clinical-stage, biopharmaceutical company developing neuroprotective, small molecule therapies for the treatment of debilitating neurological diseases, announced today the closing of more than $140 million in Series A financing.

加利福尼亚州南旧金山（商业新闻短讯）--Nura Bio Inc.（Nura Bio），一家临床阶段的生物制药公司，开发用于治疗衰弱性神经疾病的神经保护性小分子疗法，今天宣布关闭超过1.4亿美元的a系列融资。

This includes the addition of $68 million to the initial Series A round of $73 million which was announced in 2020. The round was led by founding investor The Column Group, with participation from continuing investors Samsara Bio Capital and Euclidean Capital, and new investor Sanofi Ventures..

这包括在2020年宣布的首轮7300万美元的A轮投资中增加6800万美元。本轮投资由创始投资者The Column Group牵头，持续投资者轮回生物资本和欧几里得资本以及新投资者赛诺菲风险投资公司参与。。

The company also announced the appointment of Shilpa Sambashivan, Ph.D., as Chief Executive Officer (CEO) and a company Director. As a member of the founding team at Nura Bio and Chief Scientific Officer (CSO), Dr. Sambashivan has been the driving force behind Nura Bio’s bespoke research engine and differentiated R&D pipeline, with the company’s first clinical candidate, NB-4746, recently completing Phase 1 studies in healthy volunteers..

该公司还宣布任命ShilpaSambashivan博士为首席执行官（CEO）和公司董事。作为Nura Bio创始团队的成员和首席科学官（CSO），Sambashivan博士一直是Nura Bio定制研究引擎和差异化研发渠道的驱动力，该公司的第一位临床候选人NB-4746最近完成了健康志愿者的第一阶段研究。。

“Under Shilpa’s leadership, Nura Bio has successfully transitioned to a clinical-stage organization, making remarkable progress in identifying ways to translate complex biology into potential therapies,” said Tim Kutzkey, Ph.D., Managing Partner, The Column Group and Nura Bio’s founding chairman. “We are excited to continue to support the company through this next phase of growth and clinical development.

“在Shilpa的领导下，Nura Bio已成功转型为临床阶段组织，在确定将复杂生物学转化为潜在疗法的方法方面取得了显着进展，”专栏组管理合伙人兼Nura Bio创始主席Tim Kutzkey博士说。“我们很高兴在下一阶段的增长和临床开发中继续支持公司。

Shilpa’s leadership, combined with her deep scientific expertise, will be key to maximizing Nura Bio’s broad therapeutic potential in areas of large unmet need.”.

Shilpa的领导才能，加上她深厚的科学专业知识，将是最大限度地发挥Nura Bio在大量未满足需求领域的广泛治疗潜力的关键。”。

Nura Bio’s financing close comes at a pivotal point with the Phase 1 success of NB-4746, a brain-penetrant SARM1 inhibitor that has been shown to prevent axon degeneration and provide neuroprotection in multiple preclinical models of nerve injury and disease. Nura Bio plans to initiate a Phase 1b/2 trial in a patient population in 2025..

随着NB-4746（一种脑渗透性SARM1抑制剂）的第一阶段成功，Nura Bio的融资接近关键点，该抑制剂已被证明可预防轴突变性，并在多种神经损伤和疾病的临床前模型中提供神经保护。Nura Bio计划于2025年在患者人群中启动1b/2期试验。。

“At Nura Bio, we have been laser-focused on our mission of delivering novel neuroprotective therapies to patients by leveraging our deep scientific understanding of underlying disease mechanisms including axon degeneration and neuroinflammation. The strong support demonstrated by our investors through this financing reflects the tremendous potential of our R&D pipeline,” said Dr.

“在Nura Bio，我们一直专注于通过利用我们对轴突变性和神经炎症等潜在疾病机制的深入科学理解，为患者提供新型神经保护疗法的使命。我们的投资者通过这笔资金提供的有力支持反映了我们研发渠道的巨大潜力，”Dr。

Sambashivan. “I am proud of the results our team has delivered. I look forward to leading the company through this next phase as we prepare to test the SARM1 hypothesis in a patient population in 2025 with our lead candidate NB-4746 while continuing to advance our promising preclinical pipeline.”.

桑巴西万。“我为我们团队取得的成果感到骄傲。我期待着带领公司度过下一阶段，因为我们准备在2025年用我们的主要候选人NB-4746在患者人群中测试SARM1假说，同时继续推进我们有希望的临床前管道。”。

Results from the recently completed Phase 1 study of NB-4746 in healthy volunteers show it was well-tolerated in the single ascending and multiple ascending dose arms of the study. In this Phase 1 study, NB-4746 achieved targeted plasma exposure levels that the company believes are required for efficacy with no associated serious treatment-emergent adverse events.

最近在健康志愿者中完成的NB-4746第一阶段研究的结果表明，在该研究的单次递增和多次递增剂量组中，NB-4746具有良好的耐受性。在这项第一阶段研究中，NB-4746达到了目标血浆暴露水平，该公司认为这是疗效所必需的，没有相关的严重治疗紧急不良事件。

Cerebrospinal fluid levels of NB-4746 confirm brain penetration and support this molecule's advancement in diseases that impact both the peripheral and central nervous systems..

NB-4746的脑脊液水平证实了大脑的渗透，并支持该分子在影响周围神经系统和中枢神经系统的疾病中的进展。。

About NB-4746

关于NB-4746

NB-4746 is the lead asset in Nura Bio’s small molecule pipeline. NB-4746 targets SARM1, a neuronally enriched nicotinamide adenine dinucleotide (NAD) hydrolase that has emerged as an important axon-intrinsic metabolic sensor and central driver of axon degeneration. Axon degeneration is an early hallmark of several neurological diseases.

NB-4746是Nura Bio小分子管道的主要资产。NB-4746靶向SARM1，一种富含神经元的烟酰胺腺嘌呤二核苷酸（NAD）水解酶，已成为重要的轴突内在代谢传感器和轴突变性的中枢驱动因素。轴突变性是几种神经系统疾病的早期标志。

Halting axon degeneration early can confer significant structural and functional neuroprotection and has tremendous potential in the treatment of several neurological diseases. Preclinical studies support the potential of NB-4746 to provide broad axonal protection and functional improvement across diseases of the central, peripheral, and ocular nervous systems..

早期停止轴突变性可以赋予显着的结构和功能神经保护作用，并且在治疗几种神经疾病方面具有巨大潜力。临床前研究支持NB-4746在中枢，外周和眼神经系统疾病中提供广泛的轴突保护和功能改善的潜力。。

About Nura Bio

关于Nura Bio

Nura Bio, Inc. (Nura Bio) is a clinical-stage biopharmaceutical company developing neuroprotective therapies for the treatment of a broad range of neurological diseases. Nura Bio’s research and early development small molecule pipeline is focused on developing therapies that halt axon degeneration and/or modulate microglial responses to degeneration and injury, with the goal of conferring neuroprotection, across diseases of the central, peripheral, and ocular nervous systems..

Nura Bio，Inc.（Nura Bio）是一家临床阶段的生物制药公司，开发用于治疗多种神经系统疾病的神经保护疗法。Nura Bio的研究和早期开发小分子管道专注于开发阻止轴突变性和/或调节小胶质细胞对变性和损伤反应的疗法，目的是在中枢神经系统，外周神经系统和眼神经系统疾病中提供神经保护。。